Sindbis Viral Vector E2 Mutations for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Sindbis viral vectors for cancer therapy are not sufficiently effective in targeting and reducing metastatic tumors, with existing vectors showing limited ability to specifically target tumor cells and achieve long-term survival in tumor-induced SCID mice models.
Innovation Solution
Development of new Sindbis viral vectors with specific mutations in the E2 envelope protein, such as changing Glu to Lys at position 70, and using chimeric combinations of JT and Ar-339 strains to enhance tumor targeting and replicase efficiency, along with the production of defective viral vectors using linearized replicon and helper plasmids for in vitro transcription and cell transfection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Sindbis viral vectors are used for cancer therapy, then tumor cells can be targeted and apoptosis induced, but the vectors show limited ability to specifically target tumor cells and achieve long-term survival
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues in the E2 envelope protein (positions 68, 70, 181, and 251) to alter the vector's binding affinity and specificity for tumor cells. The K70E mutation in particular demonstrated enhanced tumor targeting capability, directly resolving the contradiction between targeting efficiency and tumor reduction effectiveness.
Solution Approach 2:
The invention applies local quality by introducing site-specific mutations only in the E2 envelope protein domain responsible for cell binding, while leaving the rest of the viral structure intact. This localized modification approach allows optimization of tumor targeting without compromising overall viral function or inducing excessive immunogenicity.
2Productivity
If Sindbis vectors are administered to treat tumors, then some tumor reduction is achieved, but survival of all mice in tumor models has not yet been achieved
Solution Approach 1:
The patent uses parameter changes through multiple amino acid substitutions in the E2 protein to enhance both the potency of tumor cell killing and the specificity of targeting. The optimized vectors with mutations at positions 68, 70, 181, and 251 achieve superior tumor reduction that translates to complete survival in SCID mouse models, resolving the previous failure to achieve universal survival.
Solution Approach 2:
The invention creates composite viral vectors by combining mutated E2 envelope proteins with the Sindbis viral backbone, producing a hybrid vector system that integrates enhanced tumor targeting capabilities with effective oncolytic activity, thereby achieving both tumor reduction and long-term survival.
3Object-affected harmful factors
If existing Sindbis vectors are used, then some metastatic tumor implantation is reduced, but the ability to specifically target tumor cells is limited
Solution Approach 1:
The patent applies parameter changes by systematically mutating amino acid residues in the E2 envelope protein to optimize binding specificity for tumor cell surface receptors. The K70E mutation and other substitutions enhance affinity for metastatic tumor cells, simultaneously improving both targeting specificity and reduction of harmful metastatic implantation.
Solution Approach 2:
The invention uses local quality by introducing precise point mutations in the E2 protein's receptor-binding domain, thereby locally enhancing tumor cell recognition and binding without affecting other viral functions. This localized optimization achieves superior specificity for metastatic tumor cells.
Data Source
AI summary
Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.